REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that entered public markets through a SPAC business combination, with its shares trading under the RVPH ticker following the transaction's close. The company operates in the healthcare and life sciences sector, with its pipeline centered on central nervous system disorders, including schizophrenia, Alzheimer's disease, and related metabolic conditions, anchored by its lead candidate brilaroxazine. The December 2024 8-K filing reflects the company's continuing SEC disclosure obligations as a post-merger public registrant. For full filing history, sponsor details, merger timeline, and ongoing RVPH data, sign up for complete access at SpacDesk.